carbidopa

(redirected from Sinemet cr)
Also found in: Medical.

car·bi·do·pa

 (kär′bĭ-dō′pə)
n.
A drug, C10H14N2O4, that increases the availability of L-dopa to the brain and is administered with L-dopa to treat Parkinson's disease.

[Alteration of carbo- + dopa.]
Translations

carbidopa

n carbidopa
Mentioned in ?
References in periodicals archive ?
Sinemet CR typically enables a patient to reduce dosing frequency by one-third.
Currently taking one of the following levodopa related PD drugs: Levodopa, Dopar, Sinemet, Sinemet CR, Stalevo or Stalevo ER.
One of Depomed's formulations in the study extended the median time point at which levodopa blood levels exceeded the efficacious threshold of 300 ng/mL to approximately nine hours, compared to approximately seven hours for the generic version of Sinemet CR tested in the study.
In a head-to-head trial, Impax Laboratories/GlaxoSmithKline's emerging agent Rytary - a reformulation of levodopa (Bristol-Myers Squibb/DuPont Pharma's Sinemet, Sinemet CR, other brands, generics) - showed an effect on motor fluctuations that, consistent with our survey results, likely will be sufficient to persuade surveyed MCO pharmacy directors to include the product on formularies should the drug launch.
The objective of the study is to compare the pharmacokinetics of two distinct formulations of DM-1992 and a generic version of Sinemet CR sustained-release Levodopa/Carbidopa, as well as the safety and tolerability of the formulations.
that Merck would not file suit against KV based on KV's submission of an ANDA containing a Paragraph IV patent certification seeking approval to market a generic version of Sinemet CR (carbidopa and levodopa extended release tablets) 25mg/100mg before the expiration in June 2006 of the patents listed in the Orange Book for that product.
Sinemet CR is the carbidopa-levodopa product most prescribed by neurologists in the treatment of Parkinson's disease.
Sinemet CR is used to treat patients with Parkinsonism, and is exclusively distributed in the U.